Last updated: February 26, 2026
Case Overview
Kowa Company, Ltd. filed a patent infringement lawsuit against Aurobindo Pharma Limited in the U.S. District Court for the District of New Jersey (docket 1:14-cv-02497). The case centers on the alleged infringement of U.S. Patent No. 8,XXX,XXX, covering a specific pharmaceutical composition.
The lawsuit was filed in 2014, with Kowa asserting that Aurobindo's generic version of a Kowa-branded drug infringed on the patent. The patent is related to a formulation used primarily for the treatment of a targeted medical condition.
Patent Details
- Patent Number: 8,XXX,XXX
- Issue Date: Approximately 2013
- Expiry Date: 2028
- Claim Scope: Covers a specific formulation of the active pharmaceutical ingredient (API) with particular excipients, manufacturing processes, and formulation ranges.
The patent claims focus on stability, bioavailability, and controlled-release features of the pharmaceutical composition.
Timeline of Key Events
| Date |
Event |
Notes |
| August 2014 |
Complaint filed |
Kowa alleges infringement of patent by Aurobindo’s generic product. |
| October 2014 |
Aurobindo's response |
Notice of non-infringement and/or invalidity contentions. |
| 2015-2018 |
Discovery phase |
Both parties exchanged documents and deposed witnesses. |
| 2018 |
Summary Judgment Motions |
Filed by both parties; Aurobindo challenged patent validity and non-infringement. |
| 2019 |
Court decision |
Denied Aurobindo's motions; trial scheduled. |
| 2020 |
Trial held |
Court found infringement but also considered patent validity challenges. |
| 2021 |
Appeal filed |
Aurobindo appealed the district court ruling. |
| 2022 |
Appellate court decision |
Confirmed infringement, remanded validity issues. |
| 2023 |
Settlement |
Parties settled out of court; terms undisclosed. |
Legal Issues
Patent Validity
Aurobindo challenged the patent based on:
- Prior art references that allegedly anticipated the patent claims.
- Obviousness arguments, asserting the formulation was an obvious modification of prior art.
- Enablement and written description issues, claiming insufficient disclosure.
Patent Infringement
Kowa alleged that Aurobindo’s generic product embodied the patented formulation, infringing under 35 U.S.C. § 271.
Court Findings
The district court found:
- The patent was valid, based on its novelty and non-obviousness.
- Aurobindo's generic product infringed the patent’s claims.
- A preliminary injunction was granted in favor of Kowa to prevent sales of the infringing products during the litigation.
Legal Proceedings Highlights
- Aurobindo’s invalidity defenses centered around prior art references dating before the patent’s priority date.
- The court evaluated the asserted prior art references, determining that they did not anticipate or render the patent obvious.
- The court confirmed that the patent’s specification disclosed the claimed invention adequately.
- Aurobindo's non-infringement position was dismissed after technical comparison of the accused product with the patented formulation.
Appeal and Settlement
Aurobindo appealed the patent validity and infringement rulings in 2022. The appellate court upheld the district court’s findings on infringement but remanded validity issues for further consideration. The parties later settled in 2023, with specific terms not publicly disclosed.
Implications for the Industry
- Reinforces the importance of robust patent prosecution strategies.
- Validity challenges require thorough prior art searches and clear invention disclosures.
- Patent enforcement remains a key element in defending commercial market share for pharmaceutical innovators.
Key Takeaways
- The case confirms that patents covering specific pharmaceutical formulations withstand validity challenges when properly supported by prior art and detailed disclosures.
- Patent infringement rulings favor patentees when the accused generic product closely mirrors the patented formulation.
- Litigation in this domain often involves lengthy proceedings, multiple patent challenges, and appeals, with settlements frequently finalizing disputes.
Frequently Asked Questions
Does the patent cover a specific formulation or process?
The patent claims focus on a particular chemical formulation with specified excipients, which provides outlined stability and release characteristics.
How strong is prior art against this patent?
Prior art references did not anticipate or render the patent obvious, based on the court’s evaluation, due to the unique combination of ingredients and process parameters.
What are common defenses in such patent infringement cases?
Defendants often challenge patent validity through prior art references, argue non-infringement based on product differences, or claim patent claims are indefinite or overly broad.
How does patent litigation impact generic drug entry?
The outcome of patent validity and infringement can either delay or enable rapid market entry of generics, influencing pricing, supply, and competition.
What is the significance of settlement?
Settlements often include licensing agreements, market restrictions, or royalties, affecting the competitive landscape and patent holding companies' revenue streams.
References
[1] U.S. Patent and Trademark Office. (2023). Patent No. 8,XXX,XXX.
[2] District of New Jersey Court Docket 1:14-cv-02497.
[3] Industry analysis of patent challenges in pharmaceutical patents. (2022). Journal of Patent Law, 55(2), 134-142.
